The broad objective of this proposal is to identify antigens expressed by human pancreatic adenocarcinomas and validate these antigens as predictors of immune response. These antigens can ultimately be used in targeted cancer vaccine strategies. We have been developing an allogeneic granulocytemacrophage colony-stimulating factor (GM-CSF) secreting pancreatic tumor vaccine approach for the treatment of patients with pancreatic cancer. Recently completed phase I and II studies demonstrated the bioactivity of this vaccine as measured by elevated post-vaccination serum levels of GM-CSF, post-vaccination eosinophilia that is associated with systemic vaccine related rashes and vaccine recall reactions, and postvaccination delayed type hypersensitivity (DTH) reactions to autologous tumor. These responses are most often observed in patients demonstrating prolonged disease-free survival. Analysis of post-vaccination immune responses identified mesothelin and prostate stem cell antigen (PSCA) as two candidate new targets against which both T cell responses were directed in patients who remain disease-free. With a recently completed phase II study in resected patients, and a new currently enrolling phase II combinatorial vaccine study, we are poised to extend our immune target discovery program and to validate identified genes as immune relevant targets of the immune response.
In Aim 1, we will screen a panel of genes that are turned on early and late in pancreatic cancer progression using immunized leukopheresed lymphocytes from patients treated in our adjuvant phase II study.
In aim 2, we will validate the panel of genes evaluated in aim 1 using patient lymphocytes from two vaccine studies for their relevance as post-vaccination immune targets.
In aim 3, we will evaluate the function of T cells specific for new antigenic targets identified in aims 1 and 2. We will focus on three functional parameters: expression of lytic function, induction of memory T cells, and induction of higher avidity T cells. We will utilize tissues from clinical trials and Core 2 to translate expressed marker antigens found in proposed Project 3C (formerly 2A) to clinical trial monitoring and new trials, to prioritize candidate antigens for basic studies in proposed Project 1B, and to apply measures of host immune responses in proposed Project 2B.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA062924-18
Application #
8319273
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
18
Fiscal Year
2011
Total Cost
$235,249
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
Canto, Marcia Irene; Almario, Jose Alejandro; Schulick, Richard D et al. (2018) Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155:740-751.e2
Makohon-Moore, Alvin P; Matsukuma, Karen; Zhang, Ming et al. (2018) Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561:201-205
Chu, Nam; Salguero, Antonieta L; Liu, Albert Z et al. (2018) Akt Kinase Activation Mechanisms Revealed Using Protein Semisynthesis. Cell 174:897-907.e14
Felsenstein, Matthäus; Noë, Michaël; Masica, David L et al. (2018) IPMNs with co-occurring invasive cancers: neighbours but not always relatives. Gut 67:1652-1662
Grant, Robert C; Denroche, Robert E; Borgida, Ayelet et al. (2018) Exome-Wide Association Study of Pancreatic Cancer Risk. Gastroenterology 154:719-722.e3
Tie, Jeanne; Cohen, Joshua D; Wang, Yuxuan et al. (2018) Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. Gut :
Adler, B L; Pezhouh, M K; Kim, A et al. (2018) Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J Intern Med 283:568-577
Ma, Qianqian; Gabelli, Sandra B; Raben, Daniel M (2018) Diacylglycerol kinases: Relationship to other lipid kinases. Adv Biol Regul :

Showing the most recent 10 out of 883 publications